Stock Code: 1731

美吾華股份有限公司

Maywufa Company Limited

Handbook for the 2026 Annual Meeting of Shareholders

Form of meeting: Physical Meeting
Meeting Time: June 10, 2026
Meeting Place: 3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

I. Meeting Procedures ... 1
II. Meeting Agenda ... 2
1. Report Items ... 3
2. Acknowledged Matters ... 4
3. Election Matters ... 6
4. Other Matters ... 7
5. Extemporary Motions ... 8

III. Attachments
1. The 2025 Business Report ... 9
2. The 2025 Audit Committee’s Review Report ... 15
3. The Comparison Table of Sustainable Development Best Practice Principles ... 16
4. 2025 Independent Auditors’ Report and Financial Statements ... 19
5. Director and Independent Director Candidates ... 39
6. Details on Directors and Their Representatives Holding Concurrent Positions in Other Companies ... 44

IV. Appendices
1. Rules of Procedure for Shareholder Meetings ... 45
2. Articles of Incorporation ... 51
3. Rules for Director Elections ... 58
4. Shareholding of Directors ... 60

I. Meeting Procedures

Maywufa Company Limited
Procedure for the 2026 Annual Meeting of Shareholders

Calling the Meeting to Order (Report the total number of shares present)
Chairperson Remarks
Report Items
Acknowledged Matters
Election Matters
Other Matters
Extemporary Motions
Adjournment

II. Meeting Agenda

Maywufa Company Limited
Procedure for the 2026 Annual Meeting Agendas

Form of meeting: Physical Meeting
Meeting Time: 9:00a.m., Wednesday, June 10, 2026
Meeting Place: 3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

Call the Meeting to Order (Report the total number of shares present)
Chairperson Remarks
Report Items
(1) The 2025 Business Report.
(2) The 2025 Audit Committee’s Review Report.
(3) Report on amendment to “Sustainable Development Best Practice Principles”.
(4) 2025 employees’ and directors’ compensation.
Acknowledged Matters
(1) Adoption of 2025 the Financial Statements and Business Report.
(2) Adoption of the proposal for distribution of 2025 profits.
Election Matters
Elections of board directors.
Other Matters
Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.
Extemporary Motions
Adjournment

1. Report Items

(1) The 2025 Business Report.

Explanation: Please refer to Attachment 1 (page 9~14) for detailed Business Report.

(2) The 2025 Audit Committee's Review Report.

Explanation: Please refer to Attachment 2 (page 15) for 2025 Audit Committee’s Review Report.

(3) Report on the Revision of the “Sustainable Development Best Practice Principles”.

Explanation:
(i) In response to regulatory amendments and practical needs, relevant provisions have been added and revised concerning the new Corporate Governance Blueprint, as well as the enhancement of biodiversity and ecosystem conservation, sustainable use of resources, and fair and equitable benefit sharing. This case has been passed by the resolution of the Board of Directors on February 26, 2026, revising certain provisions of the Company's “Sustainable Development Best Practice Principles”.

(ii) Please refer to Attachment 3 (page 16~18) for The Comparison Table of “Sustainable Development Best Practice Principles”.

(iii) Report.

(4) 2025 employees’ and directors’ compensation.

Explanation:
(i) In accordance with Article 28 of the Articles of Incorporation, this Case has been passed by the resolution of the Board of Directors on February 26, 2026.

(ii) The company earned profits as NT$ 240,596,523 in 2025. Approximately 3%, or NT$ 7,222,432, was allocated as employee remuneration (20% of the employee compensation amount, totaling NTD 1,444,486, is allocated as compensation for grassroots employees.), and approximately 2%, or NT$ 4,814,953, was allocated as directors’ remuneration, both of which were paid in cash.

(iii) Report.

2. Acknowledged Matters

(1) Subject: Adoption of 2025 the Financial Statements and Business Report.

(Proposed by the Board of Directors)

Explanation: (i) The Company's 2025 Financial Statements and Business Report have been approved by the Audit Committee and the resolution of the Board of Directors on February 26, 2026. The Financial Statements have been audited by Deloitte & Touch Taipei, Taiwan Republic of China Accountants Hai-Yueh Huang and Cheng-Chuan Yu, and issued “Unqualified Opinion”.

(ii) Please refer to Attachment 1 (page 9~14) for detailed Business Report and Please refer to Attachment 4 (page 19~38) for Financial Statements.

(iii) Please acknowledge.

Resolution:

(2)Subject:Adoption of the proposal for distribution of 2025 profits.

(Proposed by the Board of Directors)

Explanation: (i). Adoption of the proposal for distribution of 2025 profits was approved by the Audit Committee and the resolution of the Board of Directors on February 26, 2026.

(ii). It is proposed to allocate NT$162,156,598 from the distributable earnings for the distribution of cash dividends, with a dividend of NT$1.22 per share. The calculation is rounded down to the nearest whole New Taiwan dollar. Any fractional dividends less than one New Taiwan dollar shall be disregarded, and the total amount of such dividends not distributed shall be included in the company's other income.

(iii). The proposal for distribution of 2025 profits : Unit: NT$

Unappropriated retained earnings for previous years	192, 118, 691
Plus: Net profit for 2025	181, 001, 792
Plus: remeasurement of defined benefit plan recognized in the retained earnings	3, 279, 955
Plus: disposals of investments in equity instruments measured at FVOCI, the cumulative gain or loss is transferred directly to retained earnings.	15, 024, 803
Adjusted unappropriated retained earnings after net profit plus other items calculated into	199, 306, 550
Less: 10% legal reserve	(19, 930, 655)
Plus: reversal of special reserve	16, 170, 435
Earnings available for distribution for 2025	387, 665, 021
Distribution Items :
Less: Common share dividends—Cash (NT$1.22 /per share)	(162, 156, 598)
Unappropriated retained earnings at the end of the period	225, 508, 423

Chairman: Lee Chen-Chia General Manager: Lai Yu-Ju Accounting Supervisor: chen Chao-Ming

(iv). Upon the approval of the Annual Meeting of Shareholders, it is proposed that the Board of Directors shall be authorized to resolve the ex-dividend date, payment date and other relevant issues.

(v). It is proposed that the Chairperson of the Board of Directors be authorized with full power and authority to adjust distribution percentage if the number of outstanding shares is affected.

(vi). Please acknowledge.

Resolution:

Election Matters

Subject: Elections of board directors. (Proposed by the Board of Directors)

Explanation:
(i). The Company currently has thirteen directors (including four independent directors). Their term of office will expire on May 25, 2026. In accordance with the Company Act, the directors may continue to perform their duties until the newly elected directors assume office following the comprehensive re-election of directors at the 2026 Annual General Meeting of Shareholders.
(ii). Pursuant to Article 17 of the Company’s Articles of Incorporation, thirteen directors (including four independent directors) shall be elected at this Annual General Meeting. The election of directors adopts the candidate nomination system, and shareholders shall elect directors from the list of nominees. The newly elected directors shall assume office on the date of election for a three-year term, from June 10, 2026 to June 9, 2029.
(iii). The list of candidates for directors and independent directors for this election was approved by the Board of Directors on February 26, 2026. Please refer to Attachment 5 (page 39~43) for Elections of Board Directors.
(iv). Please refer to Appendix 3 (page 58-59) for "Rules for Director Elections".
(v). Please conduct the election.

Election resolution:

4. Other Matters

Subject: Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business. (Proposed by the Board of Directors)

Explanation:
(i) According to Article 209 of the Company Law, if a director engages in an act within the scope of the company's business for themselves or others, they must explain the important details of their actions to the shareholders' meeting and obtain their approval.
(ii) Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business, Please refer to Attachment 6 (page 44) for details on directors and their representatives holding concurrent positions in other companies. It is proposed that the Shareholders' Meeting agree to lift the restrictions on director competition from the date of the newly elected directors' appointment.
(iii) This case has been approved by the board of directors on February 26, 2026.
(iv) Please discuss.

Resolution:

5. Extemporary Motions

6. Adjournment

III. Attachments

Attachment 1

Maywufa Company Limited

The 2026 Business Report

I.2026 Business Policy

(1). Consumer Business Unit :

(i). Maywufa® continues to maintain its leadership in the hair dye market: The Company will continue to build momentum for the emerging Black Hair Color Treatment category and introduce new brands to provide consumers with more product choices that meet their individual needs. For the young fashion hair color segment, trendy new products will continue to be launched with stylish packaging and popular hair colors favored by younger consumers to capture market attention.

(ii). Accelerating the growth of hair care brands: Maywufa® continues to develop functional shampoo and hair care products for a broader consumer base by continuously introducing new ingredients and product types, as well as skin and body care products, providing consumers with a richer and more comprehensive range of options. Through a multi-brand strategy, the Company aims to meet the diverse and evolving needs of consumers.

(iii). Enhancing overall brand exposure through both online and offline media: The Company will continue to strengthen customer loyalty, expand product lines, and increase market visibility to maintain growth momentum. In addition to maintaining cooperation with physical retail channels, Maywufa® has also established its own official website and collaborates with e-commerce platforms to achieve strong sales performance.

(iv). Mustela® has firmly established its brand image as a trusted choice for infant and maternity skincare. In response to consumer trends, the brand continues to introduce and promote natural and organic skincare products suitable for the whole family. Through strategic promotion across professional channels, consumer retail channels, and e-commerce platforms, Mustela® continues to drive overall sales growth.

(v). SAHOLEA® continues to expand its hair care product range, stimulating market demand with new product launches. The brand enhances its presence through diverse advertising and marketing strategies while optimizing its official website and strengthening partnerships with external e-commerce platforms. Additionally, it actively expands its physical retail distribution, further increasing brand visibility and sustaining strong sales momentum.

(2). Pharmaceutical Business Unit :

(i). The Pharmaceutical Division continues to promote the use and procurement of Oraphine® in medical centers and primary care institutions, while actively expanding the reach of key

self-paid products such as PG2, Cerebrolysin®, and Bio-Three®. In response to hospital workforce adjustments and the hierarchical medical care policy under National Health Insurance, a dual-track promotion strategy is employed to encourage usage in both medical centers and primary care institutions. This approach aims to deepen product penetration, broaden usage, and increase both utilization rates and market share. Furthermore, by integrating with the Group's other healthcare products, the Company promotes expanded market and clinical adoption, driving overall sales growth.

(ii). Continue to execute the "National Health Insurance Drives Self-Pay, Maximizes Self-Pay Value" strategy to increase the market share and attract new patients to use PG2. Simultaneously, amid the trend of cancer becoming a "chronic disease." We are fully committed to promoting academic seminars and clinical experience sharing meetings that combine professional depth and breadth. Through the National Health Insurance's "Real-World Evidence (RWE)" system research and in conjunction with the government's promotion of "palliative care for early-stage cancer," we will promote clinical fatigue assessment and treatment, and continue to hold clinical RWE discussion meetings and education and training on the "Clinical Treatment Guidelines for Cancer-Related Fatigue," increasing clinical healthcare professionals' use of PG2 in clinical practice to help reduce cancer-related fatigue and achieve the treatment goal of successfully completing the treatment course. Continuously expanding product visibility and enhancing growth momentum in sales.

(iii). Promoting awareness and understanding of Cancer-Related Fatigue (CRF) treatment through public education initiatives, including patient education materials, physician educational videos, and informational posters. Patients and their families are encouraged to actively discuss CRF treatment with healthcare professionals, highlighting the importance and necessity of addressing this condition. These efforts aim to continuously increase the use of PG2 and AmazPower®, driving growth and achieving outstanding results.

(iv). AmazPower® continues to collaborate with hospitals and pharmacies to ensure that our products are stocked on shelves simultaneously. By integrating with PG2®, we aim to strengthen the recommendation of our products by healthcare professionals and implement strategies to attract new patients.

(v). Cerebrolysin® has published a retrospective real-world study in collaboration with domestic clinical experts in a medical journal. By integrating international clinical treatment guidelines and academic research, its clinical value and product positioning are further enhanced. By establishing a healthcare service network connecting medical centers and primary healthcare institutions, stroke and traumatic brain injury patients can receive continuous treatment from the acute phase through post-discharge care, ensuring

comprehensive and integrated care. This approach emphasizes the clinical benefits of early and prolonged use, expanding both the duration of Cerebrolysin® use in clinical settings and the range of patient profiles suitable for treatment.

(vi). In collaboration with medical associations, academic symposiums and clinical experience-sharing sessions are held to enhance physicians' and healthcare professionals' knowledge and acceptance of Cerebrolysin®. Efforts are actively made to cultivate neurologists, neurosurgeons, and rehabilitation specialists, while identifying potential key physicians. Through in-depth visits, the clinical prescribing habits, experiences, and needs of physicians are assessed, allowing for targeted communication of product advantages and optimal usage timing. This strategy encourages habitual prescribing of Cerebrolysin®, ultimately increasing prescription volume.

(vii). Large academic educational seminars combined with in-depth case studies and discussions to increase frequency and continuously drive business growth.

II.2025 Results of Business Plan Implementation

(1). Consumer Business Unit:

(i). Hair dye products continue to maintain leadership in gray hair coverage and achieve steady growth through brand management, launching new brands such as “Rice Extract Color Foam,” “RISHIRI KONBU Color,” and “Polygonum Multiflorum” to continually stimulate the market. The fashion hair color segment maintains its leadership and sales momentum in the Taiwan hair dye market through trendy new colors. Shampoo, body wash, and hair care products remain popular with consumers, with stable sales in the fragrance series. INNEX® launched new hair masks and body lotions, Oriental introduced a relaxing sleep shower gel, all of which were well received by consumers. IngreLux® and AQILAH® shampoos continue to generate buzz, boosting sales, while Polygonum Multiflorum and Herbalism also receive positive market feedback.

(ii). Mustela®, through omnichannel promotion and physician recommendations, was voted No. 1 again in mombaby magazine’s 2025 rankings. The flagship product, “Vitamin Barrier Cream,” is used by numerous obstetrics clinics and postpartum care centers. The brand expands its positioning to whole-family skincare, participating in dermatology associations and entering professional channels to strengthen promotion. For sensitive skin care, “STELATOPIA+ Lipid-replenishing Cream” was recognized by top physicians and also validated through third-party surveys of dermatologists and pediatricians. Stelatopia is ranked as the No. 1 physician-recommended brand for dry and itchy skin care.

(iii). SAHOLEA® continues to be favored by consumers, securing a place among premium hair care brands. Offline sales continue to grow, while e-commerce performance is enhanced

through optimization of its official website and strengthened online platform partnerships. Through new media, diversified marketing strategies, and advertising exposure, the new “Ultra Satin Camellia” series successfully generated buzz and strong sales, while the “Caffeine” series also sparked a consumer rush.

(2). Pharmaceutical Business Unit :

(i). Vigorously promoted the launch of the new product Oraphine® after years of continuous effort., Oraphine® has been successfully procured and used in multiple medical centers and primary healthcare institutions. In addition to continuously submitting new drug applications to various medical institutions, we are actively organizing academic lectures and physician experience-sharing sessions to enhance clinical discussions and expand promotion efforts in other specialties requiring moderate to severe pain relief medications.

(ii). Continuing the expansion of self-pay products PG2, Cerebrolysin®, and Bio-Three® by actively facilitating their procurement in medical institutions. PG2 has achieved over 95% penetration in major hospitals and has gradually gained procurement approval from leading medical centers, driving growth in performance. Cerebrolysin® Successfully introduced into more than 20 medical centers and continues to expand in primary healthcare institutions, increasing clinical usage and procurement, with steady business growth. Bio-Three® Secured inclusion in several major medical institutions' drug lists, maintaining differentiation from competing products and focusing on deep market cultivation to steadily increase clinical usage.

(iii). Large academic and educational seminars were held with a focus on in-depth case sharing and discussion, increasing the frequency of events. In addition, clinical medical education seminars for healthcare professionals were actively organized. Throughout the year, nearly 40 large-scale seminars, over 300 product briefings, and 10 patient education activities were held. These activities covered education and training for over 500 healthcare professionals, with more than 12,500 academic promotions. Significantly increasing the use of PG2 and greatly increasing the discussion and enthusiasm for the product among healthcare professionals and cancer patients, driving growth momentum.

(iv). We collaborate with clinical experts in neurology, neurosurgery, and rehabilitation medicine to conduct a systematic review of Cerebrolysin®-related research. Through in-depth discussions at expert meetings, a consensus is formed, and empirical findings are presented.

(v). Cerebrolysin® has been procured and used in multiple medical centers and healthcare institutions, providing more comprehensive treatment and care for stroke and traumatic brain injury patients. In collaboration with domestic experts in neurology, neurosurgery, and rehabilitation, systematic reviews of Cerebrolysin®-related research have been conducted. Through in-depth discussions in expert meetings, a consensus has been formed,

leading to evidence-based publications. Additionally, partnerships with medical societies have enabled the organization of academic seminars, expert meetings, and other scientific events to share the latest clinical research and usage experiences of Cerebrolysin®. These efforts help more physicians understand the product's advantages and its impact on patient prognosis. Furthermore, collaborations with major hospitals and primary healthcare institutions have been strengthened to integrate stroke and traumatic brain injury treatment networks. By exchanging clinical experiences, the successful practice of "early use and prolonged treatment" with Cerebrolysin® is being promoted, deepening and expanding its clinical application.

(vi). Bio-Three® has strengthened its market presence in pediatrics, particularly in the treatment of pediatric gastrointestinal diseases. By sharing the latest clinical research data with physicians, the product's application has been expanded to additional medical specialties, driving continuous business growth.

(vii). The positioning of AmazPower® is as a pharmaceutical-grade health food targeting hospital channels for marketing. Increasing endorsements from healthcare professionals and positive word-of-mouth from patients further solidify its reputation and usage among consumers, with a strategy to combine with PG2 to attract new patients.

III. Budget Execution Status

According to the "Regulations Governing the Publication of Financial Forecasts of Public Companies," financial forecast information for 2025 has not been disclosed, so this item is not applicable.

IV. Financial revenue and expenditure and profitability analysis

Unit: NTD Thousand

Item		2025	2024	Increase (Decrease) %
Financial Revenue and Expenditure	Operating revenue	1,584,065	1,485,873	6.6
	Gross profit	1,001,668	961,755	4.2
	Operating income	217,367	207,238	4.9
	Non-operating income	11,192	10,817	3.5
	Profit after tax	181,002	173,232	4.5
Profitability	Return on assets (%)	5.85%	5.45%	7.3
	Return on shareholders’ equity (%)	8.48%	8.22%	3.2
	Net profit rate (%)	11.43%	11.66%	-2
	EPS (NTD)	1.36	1.3	4.6

V. Research and Development Status

Some of our products are developed and produced in-house, and the research and development status is as follows :

(1).2025 Research and Development Expenses

Item	Year	2025
Operating revenue	(A)	1,584,065 (in thousands)
R&D expenses	(B)	22,136 (in thousands)
Total number of employees	(C)	195 people
Total number of R&D personnel	(D)	9 people
R&D expense ratio	(B/A)	1.40%
Ratio of R&D personnel to total personnel	(D/C)	4.62%

(2).2025 Research and Development Achievements

In 2025, Maywufa® achieved remarkable R&D results, consecutively launching a wide range of multi-color, multi-formulation hair dyes and multifunctional hair, body, and skincare products, including Maywufa Herbal Color®, Maywufa Oriental Herb Color, Maywufa Rice Extract Color Foam®, Maywufa Rishiri Konbu Color, Ibubble, Bubble Up, Maywufa Colorful Hair Color Foam®, AQILAH®, SAHOLEA®, Premium Cool Feeling, INNEX®, Blackverse, Polygonum Multiflorum®, IngreLux®, Herbalism, Oriental Herb Soothing, Maywufa Herbal Selection, and Maywufa Super Good Luck Floral Energy and many other items. These products have been highly recognized in the market, generating excellent results.

Chairman: Lee Chen-Chia General Manager: Lai Yu-Ju Accounting Supervisor: Chen Chao-Ming

Attachment 2

Maywufa Company Limited
Audit Committee’s Review Report

We have agreed and submitted the Company’s 2025 Financial Statements to the Board of Directors and obtained the approval of the Board of Directors. The Financial Statements have been audited by Deloitte &Touch Taipei,Taiwan Republic of China engaged by the Board of Directors with an unqualified opinion in the independent auditor’s report.

We audited the Company’s 2025 Business Report and deficit compensation proposal which have been resolved by the Board of Directors and has concluded that both of them are in accordance with the related regulations. Pursuant to the regulations set forth in Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, a report is submitted as above. Please review.

Sincerely,

Maywufa Company Limited 2026 Annual General Meeting of Shareholders

Convener Of Audit Committee : Chen Hui-Yiu

February 26, 2026

Attachment 3

Maywufa Company Limited

The Comparison Table of Sustainable Development Best Practice Principles

After amendment	Before amendment	Reason for amendment
Article 3: In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance. The company shall, in accordance with the materiality principle, conduct risk assessments of environmental, social and corporate governance issues pertaining to company operations and establish the relevant risk management policy or strategy.	Article 3: In promoting sustainable development initiatives, the company shall, in its corporate management guidelines and business operations, give due consideration to the rights and interests of stakeholders and, while pursuing sustainable operations and profits, also give due consideration to the environment, society and corporate governance.	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies.
Article 15: The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment - biodiversity and human beings from their business operations: (Omitted)
6. Improve efficiency of products and services.
7. Enhance the conservation of marine and terrestrial biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and equitable benefits.	Article 15: The company is advised to take into account the effect of business operations on ecological efficiency, promote and advocate the concept of sustainable consumption, and conduct research and development, procurement, production, operations, and services in accordance with the following principles to reduce the impact on the natural environment and human beings from their business operations: (Omitted)
6. Improve efficiency of products and services.	With reference to initiatives such as the United Nations Convention on Biological Diversity, and in consideration of relevant laws and regulations on marine and nature conservation, amendments have been made to enhance the conservation of biodiversity and ecosystems, promote the sustainable use of resources, and ensure fair and reasonable benefits.

After amendment	Before amendment	Reason for amendment
Article 17 :
The company is advised to assess the current and future potential risks and opportunities that climate change may present to enterprises and to adopt related measures.

The company is advised to adopt standards or guidelines generally used in Taiwan and abroad to enforce corporate greenhouse gas inventory and to make disclosures thereof, the scope of which shall include the following:

Direct greenhouse gas emissions: emissions from operations that are owned or controlled by the company.
Indirect greenhouse gas emissions: emissions resulting from the utilization of energy such as imported electricity, heating, or steam.
Other indirect emissions: emissions resulting from corporate activities that are not indirect emissions from energy, but are from other sources of emissions owned or controlled by the company.

The company is advised to compile statistics on greenhouse gas emissions, volume of water consumption and total weight of waste and to establish policies for energy conservation, carbon and greenhouse gas reduction, reduction of water consumption or management of other wastes. The company' carbon reduction strategies should include obtaining carbon credits and be promoted accordingly to minimize the impact of their business operations on climate change. | Article 17 :
The company is advised to assess the current and future potential risks and opportunities that climate change may pose to its current and future operations, and compile statistics on greenhouse gas emissions, water consumption, and the total weight of waste. The company should also establish policies on energy conservation and carbon reduction, greenhouse gas reduction, water conservation, and other waste management measures in order to reduce the impact of its operational activities on climate change. | In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies. |
| Article 21 :
The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills.

It is advisable for the company to establish placement programs to cultivate future industry talents.

The company shall establish and | Article 21 :
The company is advised to create an environment conducive to the development of their employees' careers and establish effective training programs to foster career skills.

The company shall appropriately reflect | To promote industry-academia integration and support students' career development, the company should establish |

After amendment	Before amendment	Reason for amendment
implement reasonable employee welfare measures (including remuneration, leave and other welfare etc.) and appropriately reflect the business performance or achievements in the employee remuneration, to ensure the recruitment, retention, and motivation of human resources, and achieve the objective of sustainable operations.	its business performance or achievements in its employee compensation policies to ensure the recruitment, retention, and motivation of human resources, thereby achieving the goal of sustainable operations.	industry–academia collaboration programs to cultivate future talent for the industry.
Article 27-1 :
The company is advised to dedicate resources to cultural and art activities or the cultural and creative industry constantly through endowments, sponsorships, investments, procurements, strategic cooperation, volunteering technical services of enterprises, or other forms of support, to promote cultural development.	(New)	In accordance with the amendments to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies.
Article 31 :
The Company’s Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders’ meeting.
The same procedure shall apply to any amendments.
The principles were first established under the title “Corporate Social Responsibility Best Practice Principles for” on April 29, 2014.
The 1st revision was made on February 25, 2015.
The 2nd amendment, which also changed the name to “Sustainable Development Best Practice Principles,” was made on February 23, 2022.
The 3rd amendment was made on February 26, 2026.	Article 31 :
The Company’s Sustainable Development Best Practice Principles shall be implemented after approval by the Board of Directors and shall be reported to the shareholders’ meeting.
The same procedure shall apply to any amendments.
The principles were first established under the title “Corporate Social Responsibility Best Practice Principles” on April 29, 2014.
The 1st revision was made on February 25, 2015.
The 2nd amendment, which also changed the name to “Sustainable Development Best Practice Principles,” was made on February 23, 2022.	Addition of Amendment Frequency and Date.

Attachment 4

Financial Statements

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Maywufa Company Ltd.

Opinion

We have audited the accompanying consolidated financial statements of Maywufa Company Ltd. (the "Company") and its subsidiaries (collectively referred to as the "Group"), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to the financial statements, including material accounting policy information (collectively referred to as the "consolidated financial statements").

In our opinion, based on our audits and the report of other auditors (please refer to the Other Matter paragraph), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion based on our audits and the report of other auditors.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements for the year ended December 31, 2025. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The Validity of Occurrence of Revenue Recognition

Maywufa Group sales come from various channels, such as e-commerce, medical institutions, wholesalers and retailers, and the transaction terms are customized. For the year ended December 31, 2025, the operating revenue from some customers increased compared to the year ended December 31, 2024. Because revenues from such customers have materially influenced the Group's financial statements, we considered the validity of the occurrence of revenue recognition for the year ended December 31, 2025 a key audit matter.

For accounting policy on revenue recognition, refer to Note 4(1); for operating revenue recognition policy, refer to Note 22.

The audit procedures that we performed with respect to the sales revenue from the aforementioned customers are as follows:

We obtained an understanding of the internal controls related to the occurrence of operating revenue. We also evaluated the design of the controls and tested the operating effectiveness of the controls.
We selected samples of sales transactions from the aforementioned customers. We checked the details of the external documentation and confirmed that sales were valid and did occur.

Other Matters

We did not audit the financial statements of PhytoHealth Corporation, AmCad BioMed Corporation, and Broadsound Corporation accounted for using the equity method as of December 31, 2025 and 2024, but such statements were audited by other auditors. Our opinion, insofar as it relates to the amounts of investments accounted for using the equity method and other comprehensive income included in the consolidated financial statements for these investees, is based solely on the reports of other auditors. According to the reports of other auditors as of December 31, 2025 and 2024, the amounts of the investments accounted for using the equity method of Maywufa Group were NT$521,106 thousand and NT$510,639 thousand, respectively, both representing 16% of the consolidated total assets; the amounts of the equity accounting method - recognition of losses of Maywufa Group for the years ended December 31, 2025 and 2024 were NT$16,511 thousand and NT$17,315 thousand, respectively, representing (7%) and (8%) of the consolidated total profit before income tax, respectively.

We have also audited the parent company only financial statements of Maywufa Company Ltd. as of and for the years ended December 31, 2025 and 2024, on which we have issued an unmodified opinion and other matter paragraph on record for reference.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and the IFRS, IAS, IFRIC, and SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the

Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Hai-Yueh Huang and Cheng-Chuan Yu.

Deloitte & Touche
Taipei, Taiwan
Republic of China
February 26, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

	2025		2024
ASSETS	Amount	%	Amount	%
CURRENT ASSETS
Cash and cash equivalents (Notes 4 and 6)	$ 225,062	7	$ 175,367	6
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	-	-	12,000	-
Financial assets at amortized cost - current (Notes 4 and 8)	395,000	12	418,120	13
Notes receivable (Notes 4 and 9)	13,174	-	11,145	-
Accounts receivable (Notes 4, 9 and 29)	272,945	9	239,286	8
Other receivables (Notes 4, 9 and 29)	2,079	-	1,889	-
Inventories (Notes 4 and 10)	298,331	9	279,750	9
Prepayments	1,905	-	2,160	-
Other current assets (Note 16)	1,005	-	380	-
Total current assets	1,209,501	37	1,140,097	36
NON-CURRENT ASSETS
Financial assets at fair value through other comprehensive income - non-current (Notes 4 and 12)	136,704	5	135,606	5
Investments accounted for using the equity method (Notes 4 and 13)	523,456	16	512,968	16
Property, plant and equipment (Notes 4, 14, 29 and 30)	1,234,619	38	1,269,968	40
Right-of-use assets (Notes 4 and 15)	7,195	-	4,255	-
Intangible assets (Note 4)	7,056	-	7,072	-
Deferred tax assets (Notes 4 and 24)	36,340	1	31,669	1
Refundable deposits	5,614	-	5,163	-
Net defined benefit assets - non-current (Notes 4 and 20)	75,770	3	71,508	2
Other non-current assets (Note 16)	1,185	-	-	-
Total non-current assets	2,027,939	63	2,038,209	64
TOTAL	$ 3,237,440	100	$ 3,178,306	100
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term borrowings (Note 17)	$ -	-	$ 35,000	1
Notes payable (Note 18)	5	-	10	-
Accounts payable (Notes 18 and 29)	89,066	3	96,398	3
Other payables (Notes 19)	290,774	9	249,975	8
Current tax liabilities (Notes 4 and 24)	28,052	1	27,100	1
Lease liabilities - current (Notes 4 and 15)	2,411	-	1,818	-
Other current liabilities	22,893	-	22,255	1
Total current liabilities	433,201	13	432,556	14
NON-CURRENT LIABILITIES
Long-term borrowings (Notes 4, 17 and 30)	634,464	20	634,464	20
Deferred tax liabilities (Notes 4 and 24)	13	-	18	-
Lease liabilities - non-current (Notes 4 and 15)	4,886	-	2,504	-
Guarantee deposits (Note 29)	1,945	-	1,945	-
Total non-current liabilities	641,308	20	638,931	20
Total liabilities	1,074,509	33	1,071,487	34
EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT (Note 21)
Share capital - ordinary shares	1,329,152	41	1,329,152	42
Capital surplus	192,289	6	192,157	6
Retained earnings
Legal reserve	233,894	7	214,672	6
Special reserve	62,362	2	89,821	3
Unappropriated earnings	391,425	12	343,379	11
Total retained earnings	687,681	21	647,872	20
Other equity	(46,191)	(1)	(62,362)	(2)
Total equity	2,162,931	67	2,106,819	66
TOTAL	$ 3,237,440	100	$ 3,178,306	100

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024
	Amount	%	Amount	%
OPERATING REVENUE (Notes 4, 22 and 29)	$ 1,584,065	100	$ 1,485,873	100
OPERATING COSTS (Notes 4, 10, 20, 23 and 29)	582,397	37	524,118	35
GROSS PROFIT	1,001,668	63	961,755	65
OPERATING EXPENSES (Notes 4, 20, 23 and 29)
Selling and marketing expenses	673,994	42	636,739	43
General and administrative expenses	109,850	7	117,344	8
Expected credit impairment loss (Note 9)	457	-	31	-
Total operating expenses	784,301	49	754,114	51
OTHER OPERATING INCOME AND EXPENSES (Notes 23 and 29)	-	-	(403)	-
PROFIT FROM OPERATIONS	217,367	14	207,238	14
NON-OPERATING INCOME AND EXPENSES (Note 23)
Interest income	8,093	1	8,301	1
Other income (Note 29)	26,176	2	22,230	1
Other gains and losses	1,700	-	797	-
Interest expense	(8,287)	(1)	(3,170)	-
Share of profit or loss of associates (Notes 4 and 13)	(16,490)	(1)	(17,341)	(1)
Total non-operating income and expenses	11,192	1	10,817	1
PROFIT BEFORE INCOME TAX	228,559	15	218,055	15
INCOME TAX EXPENSE (Notes 4 and 24)	47,557	3	44,823	3
NET PROFIT	181,002	12	173,232	12
OTHER COMPREHENSIVE INCOME (Notes 4, 13, 20 and 21)
Items that will not be reclassified subsequently to profit or loss
Remeasurement of defined benefit plans	3,280	-	11,399	1
				(Continued)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024
	Amount	%	Amount	%
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	24,766	2	22,254	1
Share of the other comprehensive income of associates accounted for using the equity method	5,550	-	7,923	1
Items that may be reclassified subsequently to profit and loss
Exchange differences on translation of financial statement of foreign operations	879	-	4,871	-
Total other comprehensive income (net of income tax)	34,475	2	46,447	3
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	$ 215,477	14	$ 219,679	15
NET INCOME ATTRIBUTABLE TO:
Shareholders of the parent	$ 181,002	11	$ 173,232	12
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:
Shareholders of the parent	$ 215,477	14	$ 219,679	15
EARNINGS PER SHARE (Note 25)
Basic	$ 1.36		$ 1.30
Diluted	$ 1.36		$ 1.30

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

(Concluded)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Dividends Per Share)

	Share Capital (Note 21)	Capital Surplus (Note 21)	Retained Earnings (Note 21)			Other Equity (Note 21)		Total Equity
			Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of Foreign Financial Statements	Unrealized Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income
BALANCE ON JANUARY 1, 2024	$ 1,329,152	$ 189,320	$ 197,797	$ 106,162	$ 304,546	$ (18,070)	$ (71,751)	$ 2,037,156
Appropriation of 2023 earnings
Legal reserve	-	-	16,875	-	(16,875)	-	-	-
Reversal of special reserve	-	-	-	(16,341)	16,341	-	-	-
Cash dividends - NT$1.15 per share	-	-	-	-	(152,853)	-	-	(152,853)
Other changes in capital surplus
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	2,837	-	-	-	-	-	2,837
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 12, 13 and 21)	-	-	-	-	7,589	-	(7,589)	-
Net profit for the year ended December 31, 2024	-	-	-	-	173,232	-	-	173,232
Other comprehensive income for the year ended December 31, 2024	-	-	-	-	11,399	4,871	30,177	46,447
Total comprehensive income for the year ended December 31, 2024	-	-	-	-	184,631	4,871	30,177	219,679
BALANCE ON DECEMBER 31, 2024	1,329,152	192,157	214,672	89,821	343,379	(13,199)	(49,163)	2,106,819
Appropriation of 2024 earnings
Legal reserve	-	-	19,222	-	(19,222)	-	-	-
Reversal of special reserve	-	-	-	(27,459)	27,459	-	-	-
Cash dividends - NT$1.20 per share	-	-	-	-	(159,497)	-	-	(159,497)
Other changes in capital surplus
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	132	-	-	-	-	-	132
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 12, 13 and 21)	-	-	-	-	15,024	-	(15,024)	-
Net profit for the year ended December 31, 2025	-	-	-	-	181,002	-	-	181,002
Other comprehensive income for the year ended December 31, 2025	-	-	-	-	3,280	879	30,316	34,475
Total comprehensive income for the year ended December 31, 2025	-	-	-	-	184,282	879	30,316	215,477
BALANCE ON DECEMBER 31, 2025	$ 1,329,152	$ 192,289	$ 233,894	$ 62,362	$ 391,425	$ (12,320)	$ (33,871)	$ 2,162,931

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES
Profit before income tax	$ 228,559	$ 218,055
Adjustments for:
Depreciation expense	51,779	35,493
Amortization expense	2,603	1,928
Expected credit impairment loss	457	31
Net gain on fair value changes of financial assets at fair value through profit or loss	(317)	(95)
Interest expense	8,287	3,170
Interest income	(8,093)	(8,301)
Dividend income	(8,880)	(7,735)
Share of loss of associates	16,490	17,341
Write-down of inventories	-	5,274
Loss on disposal of property, plant and equipment	-	403
Gain on lease modification	(6)	-
Changes in operating assets and liabilities:
Financial assets at fair value through profit or loss	12,317	(11,905)
Notes receivable	(2,049)	11,491
Accounts receivable	(34,096)	(13,163)
Other receivables	(141)	1,054
Inventories	(18,769)	(27,271)
Net defined benefit assets	(982)	(367)
Prepayments	254	(848)
Other current assets	(625)	1,196
Notes payable	(5)	(115)
Accounts payable	(7,332)	12,884
Other payables	42,632	35,722
Other current liabilities	642	(3,304)
Cash generated from operations	282,725	270,938
Interest paid	(8,201)	(6,350)
Income tax paid	(51,281)	(48,893)
Net cash generated from operating activities	223,243	215,695
CASH FLOWS FROM INVESTING ACTIVITIES
Disposal of financial assets at fair value through other comprehensive income	23,668	13,753
Purchase of financial assets at amortized cost	-	(22,990)
Proceeds from disposal of financial assets at amortized cost	23,120	-
Acquisition of associates	(21,296)	(11,988)
Payments for property, plant and equipment	(12,690)	(269,419)
Disposal of property, plant and equipment	-	131
Increase in refundable deposits	(451)	-
Decrease in refundable deposits	-	176
Payments for intangible assets	(2,587)	(4,363)
		(Continued)

MAYWUFA COMPANY LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
Increase in prepayments for equipment	(4,565)	(17,241)
Interest received	8,044	8,285
Other dividends received	8,880	7,735
Net cash generated from (used in) investing activities	22,123	(295,921)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term borrowings	-	35,000
Decrease in short-term borrowings	(35,000)	-
Proceeds from long-term borrowings	-	196,571
Repayment of the principal portion of lease liabilities	(1,977)	(4,380)
Cash dividends	(159,497)	(152,853)
Net cash (used in) generated from financing activities	(196,474)	74,338
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH AND CASH EQUIVALENTS HELD IN FOREIGN CURRENCIES	803	2,774
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	49,695	(3,114)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	175,367	178,481
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 225,062	$ 175,367

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026) (Concluded)

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Maywufa Company Ltd.

Opinion

We have audited the accompanying financial statements of Maywufa Company Ltd. (the "Company"), which comprise the balance sheets as of December 31, 2025 and 2024, and the statements of comprehensive income, changes in equity and cash flows for the years then ended, and the notes to the financial statements, including material accounting policy information (collectively referred to as the "financial statements").

In our opinion, based on our audits and the report of other auditors (please refer to the Other Matter paragraph), the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

The Validity of Occurrence of Revenue Recognition

Maywufa Company Ltd.'s sales come from various channels, such as e-commerce, medical institutions, wholesalers and retailers, and the transaction terms are customized. For the year ended December 31, 2025, the operating revenue from some customers increased compared to the year ended December 31, 2024. Because revenues from such customers have materially influenced the Company's financial statements, we considered the validity of the occurrence of revenue recognition for the year ended December 31, 2025 a key audit matter.

For accounting policy on revenue recognition, refer to Note 4(1); for operating revenue recognition policy, refer to Note 21.

The audit procedures that we performed with respect to the sales revenue from the aforementioned customers are as follows:

We obtained an understanding of the internal controls related to the occurrence of operating revenue. We also evaluated the design of the controls and tested the operating effectiveness of the controls.
We selected samples of sales transactions from the aforementioned customers. We checked the details of the external documentation and confirmed that sales were valid and did occur.

Other Matters

We did not audit the financial statements of PhytoHealth Corporation, AmCad BioMed Corporation, and Broadsound Corporation accounted for using the equity method as of December 31, 2025 and 2024, but such statements were audited by other auditors. Our opinion, insofar as it relates to the amounts of investments accounted for using the equity method and other comprehensive income included in the financial statements for these investees, is based solely on the reports of other auditors. According to the reports of other auditors as of December 31, 2025 and 2024, the amounts of the investments accounted for using the equity method of Maywufa Company Ltd. were NT$521,106 thousand and NT$510,639 thousand, respectively, both representing 16% of the total assets; the amounts of the equity accounting method - recognition of losses of Maywufa Company Ltd. for the years ended December 31, 2025 and 2024 were NT$16,511 thousand and NT$17,315 thousand, respectively, representing (7%) and (8%) of the total profit before income tax, respectively.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company's or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements for the year ended December 31, 2025 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Hai-Yueh Huang and Cheng-Chuan Yu.

Deloitte & Touche
Taipei, Taiwan
Republic of China

February 26, 2026

Notice to Readers

The accompanying financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

MAYWUFA COMPANY LTD.

BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025		2024
ASSETS	Amount	%	Amount	%
CURRENT ASSETS
Cash and cash equivalents (Notes 4 and 6)	$ 147,797	5	$ 92,597	3
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	-	-	12,000	-
Financial assets at amortized cost - current (Notes 4 and 8)	395,000	12	418,120	13
Notes receivable (Notes 4 and 9)	13,174	-	11,145	-
Accounts receivable (Notes 4, 9 and 28)	272,945	9	240,742	8
Other receivables (Notes 4, 9 and 28)	2,079	-	1,889	-
Inventories (Notes 4 and 10)	292,728	9	278,248	9
Prepayments	1,709	-	2,020	-
Other current assets (Note 15)	1,005	-	380	-
Total current assets	1,126,437	35	1,057,141	33
NON-CURRENT ASSETS
Financial assets at fair value through other comprehensive income - non-current (Notes 4 and 11)	136,704	4	135,606	5
Investments accounted for using the equity method (Notes 4 and 12)	659,898	21	654,150	21
Property, plant and equipment (Notes 4, 13, 28 and 29)	1,179,648	37	1,210,009	38
Right-of-use assets (Notes 4 and 14)	7,195	-	4,255	-
Intangible assets (Note 4)	7,056	-	7,072	-
Deferred tax assets (Notes 4 and 23)	36,340	1	31,669	1
Refundable deposits	5,542	-	5,091	-
Net defined benefit assets - non-current (Notes 4 and 19)	75,770	2	71,508	2
Other non-current assets (Note 15)	1,185	-	-	-
Total non-current assets	2,109,338	65	2,119,360	67
TOTAL	$ 3,235,775	100	$ 3,176,501	100
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term borrowings (Note 16)	$ -	-	$ 35,000	1
Notes payable (Note 17)	5	-	10	-
Accounts payable (Notes 17 and 28)	89,066	3	96,398	3
Other payables (Note 18)	289,753	9	248,831	8
Current tax liabilities (Notes 4 and 23)	28,052	1	27,100	1
Lease liabilities - current (Notes 4 and 14)	2,411	-	1,818	-
Other current liabilities	22,249	-	21,594	1
Total current liabilities	431,536	13	430,751	14
NON-CURRENT LIABILITIES
Long-term borrowings (Notes 4, 16 and 29)	634,464	20	634,464	20
Deferred tax liabilities (Notes 4 and 23)	13	-	18	-
Lease liabilities - non-current (Notes 4 and 14)	4,886	-	2,504	-
Guarantee deposits (Note 28)	1,945	-	1,945	-
Total non-current liabilities	641,308	20	638,931	20
Total liabilities	1,072,844	33	1,069,682	34
EQUITY (Note 20)
Share capital - ordinary shares	1,329,152	41	1,329,152	42
Capital surplus	192,289	6	192,157	6
Retained earnings
Legal reserve	233,894	7	214,672	6
Special reserve	62,362	2	89,821	3
Unappropriated earnings	391,425	12	343,379	11
Total retained earnings	687,681	21	647,872	20
Other equity	(46,191)	(1)	(62,362)	(2)
Total equity	2,162,931	67	2,106,819	66
TOTAL	$ 3,235,775	100	$ 3,176,501	100

The accompanying notes are an integral part of the financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

MAYWUFA COMPANY LTD.

STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024
	Amount	%	Amount	%
OPERATING REVENUE (Notes 4, 21 and 28)	$ 1,582,316	100	$ 1,475,996	100
OPERATING COSTS (Notes 4, 10, 19, 22 and 28)	585,402	37	521,202	35
GROSS PROFIT	996,914	63	954,794	65
UNREALIZED GAIN ON TRANSACTIONS WITH SUBSIDIARIES	(581)	-	(267)	-
REALIZED GAIN ON TRANSACTIONS WITH SUBSIDIARIES	267	-	710	-
REALIZED GROSS PROFIT	996,600	63	955,237	65
OPERATING EXPENSES (Notes 4, 19, 22 and 28)
Selling and marketing expenses	669,941	42	633,216	43
General and administrative expenses	100,440	6	107,999	7
Expected credit impairment loss (Note 9)	457	-	31	-
Total operating expenses	770,838	48	741,246	50
OTHER OPERATING INCOME AND EXPENSES (Notes 22 and 28)	-	-	(403)	-
PROFIT FROM OPERATIONS	225,762	15	213,588	15
NON-OPERATING INCOME AND EXPENSES (Note 22)
Interest income	7,008	-	7,131	-
Other income (Note 28)	24,171	2	20,005	1
Other gains and losses	1,700	-	797	-
Interest expense	(8,287)	(1)	(3,170)	-
Share of profit or loss of subsidiaries and associates (Notes 4 and 12)	(21,795)	(1)	(20,296)	(1)
Total non-operating income and expenses	2,797	-	4,467	-
PROFIT BEFORE INCOME TAX	228,559	15	218,055	15
INCOME TAX EXPENSE (Notes 4 and 23)	47,557	3	44,823	3
NET PROFIT	181,002	12	173,232	12
				(Continued)

MAYWUFA COMPANY LTD.

STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2025		2024
	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME (Notes 4, 12, 19 and 20)
Items that will not be reclassified subsequently to profit or loss
Remeasurement of defined benefit plans	3,280	-	11,399	1
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	24,766	2	22,254	1
Share of the other comprehensive income of associates accounted for using the equity method	5,550	-	7,923	1
Items that may be reclassified subsequently to profit and loss
Exchange differences on translation of financial statement of foreign operations	879	-	4,871	-
Total other comprehensive income (net of income tax)	34,475	2	46,447	3
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	$ 215,477	14	$ 219,679	15
EARNINGS PER SHARE (Note 24)
Basic	$ 1.36		$ 1.30
Diluted	$ 1.36		$ 1.30

The accompanying notes are an integral part of the financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

(Concluded)

MAYWUFA COMPANY LTD.

STATEMENTS OF CHANGES IN EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars, Except Dividends Per Share)

	Share Capital(Note 20)	Capital Surplus(Note 20)	Retained Earnings (Note 20)			Other Equity (Note 20)		Total Equity
			Legal Reserve	Special Reserve	UnappropriatedEarnings	ExchangeDifference onTranslation ofForeign FinancialStatements	Unrealized Gain(Loss) on FinancialAssets at FairValue ThroughOtherComprehensiveIncome
BALANCE ON JANUARY 1, 2024	$ 1,329,152	$ 189,320	$ 197,797	$ 106,162	$ 304,546	$ (18,070)	$ (71,751)	$ 2,037,156
Appropriation of 2023 earnings
Legal reserve	-	-	16,875	-	(16,875)	-	-	-
Reversal of special reserve	-	-	-	(16,341)	16,341	-	-	-
Cash dividends - NT$1.15 per share	-	-	-	-	(152,853)	-	-	(152,853)
Other changes in capital surplus
Changes in capital surplus from investments in associates accounted for using the equity method(Notes 12 and 20)	-	2,837	-	-	-	-	-	2,837
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 11, 12 and 20)	-	-	-	-	7,589	-	(7,589)	-
Net profit for the year ended December 31, 2024	-	-	-	-	173,232	-	-	173,232
Other comprehensive income for the year ended December 31, 2024	-	-	-	-	11,399	4,871	30,177	46,447
Total comprehensive income for the year ended December 31, 2024	-	-	-	-	184,631	4,871	30,177	219,679
BALANCE ON DECEMBER 31, 2024	1,329,152	192,157	214,672	89,821	343,379	(13,199)	(49,163)	2,106,819
Appropriation of 2024 earnings
Legal reserve	-	-	19,222	-	(19,222)	-	-	-
Reversal of special reserve	-	-	-	(27,459)	27,459	-	-	-
Cash dividends - NT$1.20 per share	-	-	-	-	(159,497)	-	-	(159,497)
Other changes in capital surplus
Changes in capital surplus from investments in associates accounted for using the equity method(Notes 12 and 20)	-	132	-	-	-	-	-	132
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 11, 12 and 20)	-	-	-	-	15,024	-	(15,024)	-
Net profit for the year ended December 31, 2025	-	-	-	-	181,002	-	-	181,002
Other comprehensive income for the year ended December 31, 2025	-	-	-	-	3,280	879	30,316	34,475
Total comprehensive income for the year ended December 31, 2025	-	-	-	-	184,282	879	30,316	215,477
BALANCE ON DECEMBER 31, 2025	$ 1,329,152	$ 192,289	$ 233,894	$ 62,362	$ 391,425	$ (12,320)	$ (33,871)	$ 2,162,931

The accompanying notes are an integral part of the financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026)

MAYWUFA COMPANY LTD.

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(In Thousands of New Taiwan Dollars)

	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES
Profit before income tax	$ 228,559	$ 218,055
Adjustments for:
Depreciation expense	46,454	30,058
Amortization expense	2,603	1,928
Expected credit impairment loss	457	31
Net gain on fair value changes of financial assets at fair value through profit or loss	(317)	(95)
Interest expense	8,287	3,170
Interest income	(7,008)	(7,131)
Dividend income	(8,880)	(7,735)
Share of loss of subsidiaries and associates	21,795	20,296
Loss on disposal of property, plant and equipment	-	403
Write-down of inventories	-	5,274
Unrealized gain on transactions with subsidiaries	581	267
Realized gain on transactions with subsidiaries	(267)	(710)
Gain on lease modification	(6)	-
Changes in operating assets and liabilities:
Financial assets at fair value through profit or loss	12,317	(11,905)
Notes receivable	(2,049)	11,491
Accounts receivable	(32,640)	(14,619)
Other receivables	(141)	1,054
Inventories	(14,480)	(27,749)
Net defined benefit assets	(982)	(367)
Prepayments	311	(978)
Other current assets	(625)	1,196
Notes payable	(5)	(115)
Accounts payable	(7,332)	12,884
Other payables	42,751	36,184
Other current liabilities	655	(3,356)
Cash generated from operations	290,038	267,531
Interest paid	(8,201)	(6,350)
Income tax paid	(51,281)	(48,893)
Net cash generated from operating activities	230,556	212,288
CASH FLOWS FROM INVESTING ACTIVITIES
Disposal of financial assets at fair value through other comprehensive income	23,668	13,753
Purchase of financial assets at amortized cost	-	(22,990)
Proceeds from disposal of financial assets at amortized cost	23,120	-
Acquisition of associates	(21,296)	(11,988)
Payments for property, plant and equipment	(12,610)	(269,419)
Disposal of property, plant and equipment	-	131
Increase in refundable deposits	(451)	-
		(Continued)

MAYWUFA COMPANY LTD.

STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(In Thousands of New Taiwan Dollars)

	2025	2024
Decrease in refundable deposits	-	176
Payments for intangible assets	(2,587)	(4,363)
Increase in prepayments for equipment	(4,565)	(17,241)
Interest received	6,959	7,115
Other dividends received	8,880	7,735
Net cash generated from (used in) investing activities	21,118	(297,091)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term borrowings	-	35,000
Decrease in short-term borrowings	(35,000)	-
Proceeds from long-term borrowings	-	196,571
Repayment of the principal portion of lease liabilities	(1,977)	(4,380)
Cash dividends	(159,497)	(152,853)
Net cash (used in) generated from financing activities	(196,474)	74,338
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	55,200	(10,465)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	92,597	103,062
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 147,797	$ 92,597

The accompanying notes are an integral part of the financial statements.

(With Deloitte & Touche auditors' report dated February 26, 2026) (Concluded)

Attachment 5

Maywufa Company Limited

Director and Independent Director Candidates

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
1	Director	Cheng Yi Investment Company Ltd. Representative: Lee Chen-Chia	Male	Honorary PH.D, National Taipei University Of Technology. EMBA, National Chengchi University. B.Pharma.,School Of Pharmacy, Kaohsiung Medical University.	Fonder/Chairman, Phytohealth Corp. Founder/Chairman, Amcad Biomed Corp. Chairman, Broadsound Corp. National Policy Consultants,Presidential Palace. Director, Central Bank Of The Republic Of China (Taiwan). Representatives Of The National Assembly. Director, Straits Exchange Foundation. Chairman, Taiwan Federation Of Industry. Chairman, Taiwan Province Industry Association.	Chairman, Maywufa Company Ltd. Founder /Director, Phytohealth Corp. Fonder /Director, Amcad Biomed Corp. Chairman, Taiwan Incubator SME Development Corporation.	23,594,819	N.A.
2	Director	Cheng Yi Investment Company Ltd. Representative: Lee Yi-Li	Female	Owner/President Management,Harvard Business School. MBA, Rutgers University. BBA In Finance, National Taiwan University.	Supervisor, Taiwan Bio Industry Organization Fierce Women in Biopharma, Taiwan 2016. Vice President, International Global Corporate Standard Chartered Bank. Vice President, Credit Agricole Corporate And Investment Bank. Manager, Corporate Banking Group, Citibank, N.A.	Vice Chairman, Maywufa Company Ltd. Chairman, Phytohealth Corp. Chairman /General Manager,Amcad Biomed Corp. Chairman, Broadsound Corp. Director, Maywufa Cosmetics (Shanghai) Co., Ltd. Director, Taiwan Incubator SME Development Corp. Independent Director, Sinyi Realty Inc.	23,594,819	N.A.
3	Director	Li Ling Investment Company Ltd. Representative: Lee I-Lin	Female	MBA, Carnegie Mellon University. B.ACC., National Taiwan University.	Product Manager, (Sales And Marketing), Janssen Pharmaceutical Factory Of Johnson & Johnson. Auditor/Risk Assessment Consultant, Deloitte Taiwan. Fierce Women in Biopharma, Taiwan 2025. Ten Outstanding Young Woman of the R.O.C.(2026).	Executive Director, Maywufa Company Ltd. Vice Chairman/, General Manager, Phytohealth Corp., Vice Chairman, Amcad Biomed Corp. Vice Chairman, Broadsound Corp. Supervisor, Maywufa Cosmetics (Shanghai) Co., Ltd. Supervisor, Taiwan Bio Industry Organization.	14,946,556	N.A.

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
4	Director	Cheng Yi Investment Company Ltd. Representative: Lai Yu-Ju	Male	MBA, UCLA. BBA, National Taiwan University.	Vice President, Citibank, Taiwan. 2012 Ernst & Young Entrepreneur Of The Year Award.	Director /General Manager, Maywufa Company Ltd. Director, Phytohealth Corp. Chairman, Maywufa Cosmetics (Shanghai) Co.,Ltd. Director, Taiwan Incubator SME Development Corp.	23,594,819	N.A.
5	Director	Cheng Yi Investment Company Ltd. Representative: Lee Yu-Chia	Male	EMBA, National Taiwan University Of Science And Technology.	Director, Commerce Development Research Institute. Vice Chairman, Small And Medium Enterprise Foundation ,Taiwan. Committee Member,Ministry Of Health And Welfare.	Director, Maywufa Company Ltd. Director, Taiwan Incubator SME Development Corp. Director, Mender International Co., Ltd. Chairman, Yi Xin International Company Ltd. Managing Director,National Association Of Small & Medium Enterprises ,R.O.C. Director, Small And Medium Enterprise Credit Guarantee Fund Of Taiwan. Independent Director, Pershing Technology Services Corp.	23,549,819	N.A.
6	Director	Li Ling Investment Company Ltd. Representative: Lee Bi-Jen	Female	EMBA,Royal Roads University.	Supervisor, Maywufa Company Ltd. Supervisor, Triad International Corporation. Founder, Caribbean Industrial Company. President, Rotary Club of Taipei New Century President, Distinguished Ladies Club. Supervisor, Phytohealth Corp.	Director, Maywufa Company Ltd. Chairman, Triad International Corporation. Chairman , Caribbean Industrial Company. Chairman, Bi Yi International Ltd. Supervisor, Yi Xin International Company Ltd.	14,946,556	N.A.
7	Director	Li Ling Investment Company Ltd. Representative: Yu Chang-Min	Male	MBA, National Chengchi University. B.Eng., National Taiwan University.	Sales Assistant Manager, Procter & Gamble Taiwan Ltd.	Director /Deputy General Manager Of Business Unit,Maywufa Company Ltd.	14,946,556	N.A.

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
8	Director	Hua Wei Ltd. Representative: Liu Wen-Cheng	Male	MBA, Northrop University. B.ACC., Soochow University.	Chairman, Taiwan Corporate Governance Association. Vice Chairman, Taiwan Corporate Governance Association. Independent Director, Global Unichip Corp. Independent Director, Vanguard International Semiconductor Corporation. Chairman /General Manager, Bristol-Myers Squibb Company, Taiwan. Deputy Managing / Chief Financial Officer, Bristol-Myers Squibb Company,Taiwan.	Director, Maywufa Company Ltd. Executive Director, Taiwan Corporate Governance Association. Independent Director,Advantech Co., Ltd. Independent Director,Chenbro Micom Co., Ltd.	78,000	N.A.
9	Director	Hua Wei Ltd. Representative: Lai Shu-Tzu	Female	Business Administration,Overseas Chinese University.	Deputy General Manager, Chuan Lian Enterprise Co., Ltd. Senior Advisor To The Chairman's Office, Chuan Lian Enterprise Co., Ltd./ Chief Operating Officer, Rt-Mart International Ltd. Director,PX Mart Pei-Hua Social Welfare Foundation. Director, Hwatai Bank.	Vice President,Taiwan Souji Association. President ,Global Federation Of Chinese Business Women Of Chinese Chairwomen Chapter. Independent Director, Green Solution Technology Co., Ltd.	78,000	N.A.
10	Independent Director	Chen Hui-Yiu	Male	BS In AS, National Taiwan University.	Vice Chairman, Choice Development, Inc. Independent Director, Everlance Co., Ltd. Director, Microloops Co.,Ltd. Independent Director, Senao Networks, Inc.	Independent Director, Maywufa Company Ltd. Chairman, Choice Development, Inc. Director,Transglobe life Insurance Inc. Director,LIA-ROC. Independent Director, TCM Biotech International Corp. Independent Director,TECO Electric & Machinery Co., Ltd. Director, Shihlin Development Company Ltd.	0	YES (Remarks1)

No	Candidate category	Name	Gender	Academic Qualifications
11	Independent Director	Ou Shu-Fan	Female	Dms, Guangzhou Jinan University.
CEIBS Global EMBA, Chinese-Western Graduate of Integrated.
M.D,China Medical University.	Industry Consultant, National Taiwan University Innovation Incubation Center Review Physician, Taiwan Medical.
Association Of National Health Insurance Global Budget Payment System Executive Committee.
Ophthalmologist, Cardinal Tien Hospital.
Ophthalmologist, Taipei City Hospital Zhongxiao Branch.
Ophthalmologist, Cathay General Hospital.
Ophthalmologist,Taiwan University Hospital.	Independent Director, Maywufa Company Ltd.
Chairman, Universal Vision Biotechnology Co., Ltd.
Independent Director, Gudeng Precision Industrial Co., Ltd.
Vice President, National Association Of Small & Medium Enterprises R.O.C.
Director, Ten Outstanding Young Persons Foundation.
Honorary President , Global Federation Of Chinese Business Women Of Chinese Chairwomen Chapter.
Executive director, Global Federation Of Chinese Business Women Of Chinese Chairwomen Chapter.
President,Taipei Neihu Technology Park Development Association.
Vice President,Taiwan Tai-Fu Startup Association.
Vice President,NTU E-Seed Alumni Association.
President,World Taiwanese Chambers of Commerce.
Director, Taiwan Visual Optics And Refraction Associatio.
Director, Taiwan University Industry Development Association.	0	NO
12	Independent Director	Chang Hong-Jen	Male	M.S.,Harvard University.
M.S.,National Taiwan University.
M.D.,National Yang-Ming University.	Deputy Director,Ministry Of Health And Welfaregeneral.
Manager,National Health Insurance Administration.
Director,Taiwan Centers For Disease Control.
Adjunct Professor, Institute of Public Health, National Yang Ming Chiao Tung University.
Director,Medeon Biodesign,Inc.
Director,Taiwania Capital Management Corp.
General Manager,Taiwan Global Biofund.
Chairman /Vice President, Taiwan Research-based Biopharmaceutical	Independent Director, Maywufa Co.,Ltd.
Chairman/CEO,Yfy Biotech Management Co.,Ltd.
Chairman,Micareo Taiwan,Inc.
Chairman,Micareo,Inc.
Chairman, Eusol Biotech Co.,Ltd.
Chairman, Xiangyong Biotechnology Corp.
Director, aigen Medical R&D Co.,Ltd.
Director, aigen Biotechlogy Co.,Ltd.
Director,Universal Vision Biotechnology Co., Ltd.
Director, TCCD Angels Investment Co.,Ltd.	0	NO

No	Candidate category	Name	Gender	Academic Qualifications	Experience	Current post	No. Of Shares Currently Held (shares)	Remarks
					Manufacturers Association(TRPMA). Director,Abprotix Inc. Director,Lifemax Healthcare International Corporation. Director,Jiangsu KCI Biotechnology Co., Ltd. Director, AmMax Bio Inc. Director,Jiangsu Kerunqi Biotechnology Co., Ltd.(KMQ) Director,Sequential Medicine Ltd. Director,Acepodia Biotechnologies Ltd. Director,Excelsior Biopharma Inc. Director,Taiwania Capital Biotechnology Corp. Director,Formosa Pharmaceuticals,Inc. Independent Director,TOT Biopharm Co.,Ltd.
13	Independent Director	Lin Chi-Feng	Male	Master of Science in Management, Baker University.	Assistant Manager, Citibank, Taiwan. Assistant Manager,First Securities Investment Trust Co., Ltd. Deputy General Manager,CIGNA Taiwan Life Assurance company Ltd. Manager, fubon Marketing Consultants, Inc. Chairman / General Manager,Momo.Com Inc.	Independent Director, Maywufa Co.,Ltd. Senior Consultant,Momo.Com Inc. Director,ChainSea Information Integration Co., Ltd. Director,Deesse Vivante Biomedical Technology Co., Ltd. Vice Chairman,Taiwan Consulting Group. Chairman, World Vision Taiwan.	0	NO

Remarks :Reasons for serving as independent director for three consecutive terms.
Remarks1: Chen Hui-Yiu, the candidate for independent director, has served as an independent director of the company for more than three terms. His continued nomination is based on his work experience in business and corporate operations, which allows him to leverage his expertise.

Attachment 6

Maywufa Company Limited
Details on Directors and their representatives Holding Concurrent Positions in Other Companies

Position	Name	Positions Concurrently Held In Other Companies At Present
Director	Cheng Yi Investment Company Ltd.
Representative: Lee Chen-Chia	Director, Phytohealth Corp.
Director	Cheng Yi Investment Company Ltd.
Representative: Lee Yi-Li	Chairman, Phytohealth Corp.
		Chairman /General Manager,Amcad Biomed Corp.
		Chairman, Broadsound Corp.
Director	Cheng Yi Investment Company Ltd.
Representative: Lai Yu-Ju	Director, Phytohealth Corp.
Director	Cheng Yi Investment Company Ltd.
Representative: Lee Yu-Chia	Director, Phytohealth Corp.
		Director , Mender International Co., Ltd.
Corporate Director	Li Ling Investment Company Ltd.	Corporate Director, Phytohealth Corp.
Directors	Li Ling Investment Company Ltd.
Representative: Lee I-Lin	Vice Chairman/ General Manager, Phytohealth Corp.,
		Vice Chairman, Amcad Biomed Corp.
		Vice Chairman, Broadsound Corp.
Corporate Directors	Hua Wei Ltd.	Corporate Director, Phytohealth Corp.
Independent Director	Chen Hui-Yiu	Chairman, Choice Development, Inc.
		Independent Director, TCM Biotech International Corp
Independent Director	Ou Shu-Fan	Chairman, Universal Vision Biotechnology Co., Ltd.
Independent Director	Chang Hong-Jen	Chairman, Yfy Biotech Management Co.,Ltd.
		Chairman, Micareo Taiwan,Inc.
		Chairman, Micareo, Inc.
		Chairman, Eusol Biotech Co.,Ltd.
		Chairman, Xiangyong Biotechnology Corp.
		Director, aigen Medical R&D Co.,Ltd.
		Director, aigen Biotechlogy Co.,Ltd.
		Director, Universal Vision Biotechnology Co., Ltd.
Independent Director	Lin Chi-Feng	Director, Deesse Vivante Biomedical Technology Co., Ltd.

IV. Appendices

Appendix 1

Maywufa Company Limited
Rules of Procedure for Shareholder Meetings

Article 1: Unless otherwise specified by laws and regulations, the shareholders' meeting of our company shall be conducted in accordance with these rules.

The shareholder meeting of our company shall be convened by the Board of Directors, unless otherwise provided by law. Any changes to the manner of convening the shareholder meeting shall be decided by the Board of Directors and shall be made no later than before the notice of the shareholder meeting is sent out.

Article 2: Our company should specify in the meeting notice the reporting time, reporting location, and other matters to be noted for shareholders, including shareholders, invitees, and proxy agents (hereinafter referred to as "shareholders").

The reporting time for shareholders in the preceding paragraph should be at least thirty minutes before the start of the meeting; the reporting location should be clearly marked, and sufficient and competent personnel should be assigned to handle it. For shareholders attending the video conference, registration should be accepted on the video conference platform at least thirty minutes before the meeting begins. Shareholders who complete the registration are considered to be personally attending the shareholder meeting.

Shareholders should attend the shareholder meeting with an attendance certificate, attendance sign-in card, or other attendance documents. Our company shall not arbitrarily require shareholders to provide additional proof of attendance beyond the documents relied upon by shareholders. Invitees who are required to present an authorization letter should also bring identification documents for verification.

For shareholder meetings conducted via video conference, shareholders wishing to attend via video should register with the company at least two days before the meeting.

For shareholder meetings conducted via video conference, our company should upload the agenda, annual report, and other relevant documents to the video conference platform at least thirty minutes before the meeting begins, and continue to disclose them until the meeting concludes.

Article 2-1: When our company convenes a shareholder meeting via video conference, the following matters shall be specified in the notice of the shareholder meeting:

Methods for shareholders to participate in the video conference and exercise their rights.
Measures for handling obstacles arising from natural disasters, emergencies, or other force majeure events affecting the video conference platform or participation via video, including at least the following:

(i) Procedures for handling situations where obstacles occur before the meeting, causing the postponement or continuation of the meeting, including the new time for the postponed or continued meeting.
(ii) Shareholders who did not register to participate via video in the original shareholder meeting shall not be allowed to participate in the postponed or continued meeting.
(iii) If it is not possible to continue the video conference, and after deducting the shares represented by those who participated via video, the total number of shares

represented at the meeting still meets the legal quorum requirement, the shareholder meeting shall proceed, and the shares represented by those participating via video shall be counted towards the total shares represented. These shareholders shall be deemed to have abstained from voting on all agenda items of that shareholder meeting.

(iv) The results of all motions have been announced but no provisional motions have been made. The handling method must be explained.

When convening a video shareholder meeting, appropriate alternative measures provided by shareholders who have difficulty participating via video shall be specified.

Article 3: Attendance and voting at shareholder meetings shall be based on shareholding. The number of shares represented shall be calculated based on the signatures in the attendance register or the sign-in cards submitted, as well as the number of shares reported on the video conference platform. Additionally, the number of shares for which voting rights are exercised in writing or electronically shall also be included in the calculation.

Article 4: The location for convening shareholder meetings shall be at the company's registered office or at a location convenient for shareholders to attend and suitable for holding the shareholder meeting. The meeting start time shall not be earlier than 9:00 a.m. or later than 3:00 p.m.

When our company convenes a video shareholder meeting, it is not bound by the aforementioned location restrictions.

Article 5: If the shareholders' meeting is convened by the Board of Directors, the chairman shall be the chairman of the board. In the event that the chairman of the board is absent or unable to perform his/her duties for any reason, the vice chairman shall act as his/her proxy. If there is no vice chairman, or if the vice chairman is also absent or unable to perform his/her duties for any reason, the chairman shall designate one of the executive directors to act as his/her proxy. If there is no executive director, the chairman shall designate one of the directors to act as his/her proxy. If the chairman fails to designate a proxy, one shall be selected by mutual recommendation of the executive directors or directors. If the shareholders' meeting is convened by a person other than the Board of Directors, the chairman shall be the person who has the right to convene the meeting.

Article 6: The company may appoint its commissioned lawyers, accountants, or relevant personnel to attend the shareholders' meeting. The staff in charge of the shareholders' meeting affairs shall wear identification cards or armbands.

Article 7: The company shall record the entire proceedings of the shareholder meeting through audio or video recording and preserve it for at least one year. However, if a lawsuit is filed by a shareholder under Article 189 of the Company Act, the recordings shall be preserved until the conclusion of the litigation.

In the case of a shareholder meeting held via video conference, the company shall record and preserve data such as registration, attendance, questioning, voting, and the company's vote tally results. Additionally, continuous and uninterrupted audio and video recordings of the entire video conference shall be maintained.

The aforementioned data and audio-video recordings shall be properly preserved by the company throughout their retention period. The company shall provide the entrusted party responsible for handling video conference affairs with the recordings for safekeeping.

Article 8: When the meeting time has arrived, the chairperson shall promptly announce the commencement of the meeting and simultaneously disclose the number of votes without voting rights and the total shares represented.

However, if there are not enough shareholders present representing over half of the total issued shares, the chairperson may announce a postponement of the meeting. The meeting may be postponed twice at most, and the total duration of postponements shall not exceed one hour. If after two postponements there are still insufficient shareholders present, but shareholders representing over one-third of the total issued shares are in attendance, the chairperson shall declare the meeting adjourned. In the case of a shareholder meeting held via video conference, the company shall also announce the adjournment on the video conference platform.

If after two postponements there are still insufficient shareholders present, but shareholders representing over one-third of the total issued shares are in attendance, the chairperson may, in accordance with Article 175, paragraph 1 of the Company Act, proceed with a provisional resolution and notify all shareholders to reconvene the meeting within one month. For a shareholder meeting held via video conference, shareholders wishing to attend via video shall register again with the company in accordance with Article 2.

Before the conclusion of the current meeting, if the shares represented by attending shareholders reach more than half of the total issued shares, the chairperson may resubmit the provisional resolution made according to Article 174 of the Company Act for a vote by the shareholders.

Article 9: If the shareholder meeting is convened by the Board of Directors, its agenda shall be determined by the Board of Directors. Relevant agenda items (including ad hoc motions and amendments to original proposals) shall be discussed and voted on separately, with the meeting proceeding according to the predetermined agenda, which may not be changed without the resolution of the shareholder meeting.

If the shareholder meeting is convened by a person other than the Board of Directors, the provisions of the preceding paragraph shall apply mutatis mutandis.

Before the conclusion of the agenda items set forth in the preceding two paragraphs, the chairperson may not adjourn the meeting without a resolution. If the chairperson violates the rules of procedure by adjourning the meeting, the other members of the Board of Directors shall promptly assist the shareholders present in accordance with the statutory procedure to elect, with the consent of the majority of the voting rights present, a new chairperson to continue the meeting. After the meeting is adjourned, shareholders may not elect a new chairperson to continue the meeting at the same venue or find another venue.

The chairperson shall provide ample explanation and discussion opportunities for agenda items, proposed amendments, or ad hoc motions raised by shareholders. When it is deemed that a sufficient level of discussion has been reached, the chairperson may announce the cessation of discussion, put the matter to a vote, and arrange an adequate voting period.

Article 10: When attending a shareholder meeting and wishing to speak, a shareholder must first fill out a speaking slip indicating the topic, shareholder account number (or attendance certificate number), and name, and the order of speaking will be determined by the chairperson. Shareholders who only provide a speaking slip but do not actually speak will be considered as not having spoken. If the content of the speech does not match the information on the slip, the speech content will be the official record. When a shareholder is

speaking, other shareholders may not speak or disrupt the meeting without the consent of the chairperson and the speaking shareholder. The chairperson should intervene to stop any violations.

Each shareholder may not speak more than twice on the same resolution without the consent of the chairman, and each speech shall not exceed five minutes.

If a shareholder's speech violates the regulations or goes beyond the scope of the topic, the chairman may stop him or her from speaking.

When a corporate shareholder appoints two or more representatives to attend a shareholder meeting, only one representative may speak on the same agenda item.

After a shareholder speaks during the meeting, the chairperson may personally respond or designate relevant personnel to respond.

For shareholder meetings held via video conference, shareholders participating via video may submit questions in writing on the video conference platform from the time the chairperson announces the start of the meeting until the adjournment of the meeting. Each shareholder may ask questions on each agenda item up to two times, with a limit of 200 words per question. This provision does not apply to the regulations from the first to the fifth items.

Article 11: The decision on agenda items shall be approved by a majority vote of the voting rights present, unless otherwise stipulated by the Company Law or Our company's articles of association. During the voting, the total voting rights of the attending shareholders shall be announced by the chairperson or their designated personnel, after which the shareholders shall proceed to vote.

In cases where there are amendments or alternative proposals for the same agenda item, the chairperson shall determine the order of voting in conjunction with the original proposal. If one of the proposals has already been approved, the others shall be deemed rejected and not subjected to further voting.

The scrutineers and vote counters for the voting on agenda items shall be appointed by the chairperson, but scrutineers must hold shareholder status.

The vote counting for shareholder meeting resolutions or elections shall be conducted publicly within the shareholder meeting venue, and the results shall be announced on the spot after the counting is completed, including the tally of votes, and recorded.

For Our company's video conference shareholder meetings, shareholders participating via video conferencing shall conduct voting on agenda items and election resolutions through the video conference platform after the chairperson announces the start of the meeting. All voting must be completed before the chairperson announces the end of voting; otherwise, it will be considered as abstention.

For shareholder meetings held via video conference, a single vote count shall be conducted by the chairperson after the announcement of the end of voting, and the decision and election results shall be announced.

When Our company holds a video-assisted shareholder meeting, shareholders who have registered to attend the meeting via video conferencing and wish to attend the physical shareholder meeting in person shall withdraw their registration by the second day before the meeting. Failure to withdraw in time will result in only being able to attend the shareholder meeting via video conferencing.

Shareholders who have exercised their voting rights in writing or electronically and have not withdrawn their expression of intent, and who are also participating in the shareholder meeting via video conferencing, except for ad hoc motions, may not exercise their voting rights again on the original agenda items or propose amendments to the original agenda items or exercise voting rights on amendments to the original agenda items.

Article 12: For shareholder meetings held via video conference, the minutes of the meeting shall include, in addition to the matters required by regulations, the start and end time of the meeting, the method of convening the meeting, the names of the chairperson and the recorder, as well as the handling methods and outcomes in case of obstacles occurring on the video conference platform or with participation via video due to natural disasters, emergencies, or other force majeure events.

When Our company convenes a video shareholder meeting, in addition to complying with the provisions of the preceding paragraph, the minutes of the meeting shall also specify the alternative measures provided by shareholders who have difficulty participating in the shareholder meeting via video.

Article 13: The number of shares solicited by the solicitor, the number of shares represented by the proxy agent, and the number of shares represented by shareholders attending in writing or electronically shall be compiled by Our company into a statistical table in the prescribed format on the day of the shareholder meeting and prominently displayed within the shareholder meeting venue. For shareholder meetings held via video conference, Our company shall upload the aforementioned information to the video conference platform at least thirty minutes before the start of the meeting and continue to disclose it until the meeting concludes.

When Our company convenes a video conference shareholder meeting, the total number of shares represented by attending shareholders shall be announced on the video conference platform at the commencement of the meeting. If there are additional statistics regarding the total shares represented by attending shareholders and the total voting rights during the meeting, they shall also be disclosed in the same manner.

Article 14: For shareholder meetings held via video conference, Our company shall promptly disclose the voting results and election outcomes of each agenda item on the video conference platform immediately after the conclusion of the voting, in accordance with regulations.

Article 15: When Our company convenes a video conference shareholder meeting, the chairperson and the recorder shall be located at the same place within the country. Additionally, the chairperson should announce the address of this location at the commencement of the meeting.

Article 16: During the meeting, the chairperson may announce a break at his/her discretion.

Article 17: For shareholder meetings held via video conference, at the announcement of the meeting, in addition to the matters exempted from postponement or continuation of the meeting as stipulated in Article 44-20, paragraph 4 of Regulations Governing the Administration of Shareholder Services of Public Companies, if obstacles persist on the video conference platform or with participation via video for more than thirty minutes due to natural disasters, emergencies, or other force majeure events before the chairperson adjourns the meeting, the date for postponement or continuation of the meeting shall be announced within five days, without applying the provisions of Article 182 of the Company Act.

Shareholders who were not registered to participate in the original shareholder meeting via video may not participate in the postponed or continued meeting.

For shareholder meetings that require postponement or continuation as per the first paragraph, shareholders who were registered to participate in the original shareholder meeting via video and completed the registration process but did not participate in the postponed or continued meeting shall have their shares, voting rights, and election rights counted towards the total shares, voting rights, and election rights of attending shareholders in the postponed or continued meeting.

When handling the postponement or continuation of shareholder meetings as per the first paragraph, matters for which voting and vote counting have been completed, and decisions or lists of elected directors have been announced, do not need to be reconsidered or decided again.

When Our company holds a video-assisted shareholder meeting and the video conference cannot continue as per the first paragraph, if the total shares represented still meet the statutory quorum for convening the shareholder meeting after deducting the attendance via video conferencing, the meeting shall continue without the need for postponement or continuation as per the first paragraph.

In cases where the meeting should continue as per the preceding paragraph, the shares represented by shareholders participating via video conferencing shall be counted towards the total shares represented, but they shall be considered as abstentions for all agenda items of that shareholder meeting.

Article 18: When Our company holds a video conference shareholder meeting, appropriate alternative measures should be provided for shareholders who have difficulty participating in the shareholder meeting via video.

Article 19: The chairperson may direct the security personnel (or security guards) to assist in maintaining order in the meeting venue. When the security personnel (or guards) are present to assist in maintaining order, they should wear armbands marked with the words "Security Personnel."

Article 20: These rules shall come into effect upon approval by the shareholder meeting, and the same shall apply to any amendments.

Appendix 2

Maywufa Company Limited
Articles of Incorporation

Chapter I. General

Article 1：The company is organized in accordance with the provisions of the Company Law of R.O.C. The Chinese name is 美香華股份有限公司 and the English name is Maywufa Company Ltd.

Article 2：The business scope of the company is as follows：

Manufacturing, processing, distribution, wholesale, and agency of various hair care products (cleansers) and soaps.
Manufacturing, processing, distribution, wholesale, and agency of various cosmetics (except for highly toxic ones), as well as department store business (manufacturing and processing of cosmetics limited to major factories).
Distribution, wholesale, and retail business of various beauty products, health products, and sports equipment.
Agency, distribution, wholesale, and retail business of various foods, small household appliances, apparel, and daily necessities.
Commissioning construction companies to build national housing, commercial buildings for rent or sale, and community development research and analysis consulting services (excluding architect services).
Introduction of housing rental and sales.
Retail and wholesale business of vitamin pills, oral liquid supplements, and nutrition supplements.
Buying and selling, wholesale, and retail business of medicines and medical equipment.
Wholesale and retail business of foods, baby products, and general foods containing added vitamins, amino acids, and mineral supplements.
Consulting and analysis services for pharmacy management.
Buying and selling of medical and healthcare journals and magazines.
Planning, design, management, consulting, diagnosis, and analysis consulting services for environmental protection engineering (excluding architect services).
Treatment, design, contracting, and construction business for environmental protection engineering such as exhaust gas, dust collection, noise, and smoke.
Buying and selling of various machinery and construction materials.
Buying and selling, processing, and manufacturing of pet supplies and pet food.
Import and export trade business of the aforementioned products and distribution, wholesale, buying and selling, and agency of related goods and equipment.
F219010 retail business of electronic materials.
F119010 wholesale business of electronic materials.

19.F207030 retail business of cleaning supplies.
20.F107030 wholesale business of cleaning supplies.
21.C802090 Manufacture of cleaning products
22.C802060 Manufacture of animal medicines
23.C802071 Manufacture of pesticides
24.C802080 Manufacture of environmental medicines
25.C802110 Manufacture of cosmetic pigments
26.C199990 Miscellaneous food manufacturing (such as Lingzhi, pollen, royal jelly)
27.F107120 Wholesale of precision chemical materials
28.F107020 Wholesale of dyes and pigments
29.F107170 Wholesale of industrial additives
30.F107190 Wholesale of plastic films and bags
31.F107070 Animal medicine wholesale industry
32.F107080 Environmental medicine wholesale industry
33.F108021 Western medicine wholesale industry
34.F108051 Cosmetics and pigment wholesale industry
35.F108060 Traditional Chinese medicine wholesale industry
36.F203010 Food and beverage retail industry
37.F601010 Intellectual property industry
38.G801010 Warehousing industry
39.I103050 Entrepreneurial investment business management consulting industry
40.I104010 Nutrition consulting industry
41.IC01010 Pharmaceutical testing industry
42.I301010 Information software service industry
43.I301020 Data processing service industry
44.I301030 Electronic information supply service industry
45.IZ06010 Warehousing and packaging industry
46.IZ99990 Other business services industry (development of toxicology testing and analysis equipment)
47.E603050 Automatic control engineering industry
48.E605010 Computer equipment installation industry
49.E701010 Communication engineering industry
50.F118010 Information software wholesale industry
51.F218010 Information Software Retail Industry
52.F113070 Telecommunications Equipment Wholesale Industry
53.F213060 Telecommunications Equipment Retail Industry
54.F401010 International Trade Industry
55.IG01010 Biotechnology Services Industry

56.ZZ99999 In addition to the permitted businesses mentioned above, other businesses that are not prohibited or restricted by law may be operated.

Article 3: The company may arrange mutual guarantee business with related companies or businesses in the same industry as required by its business needs.

Article 4: The company's investments in other businesses shall not be subject to the provisions of Article 13 of the Company Act regarding the total amount of investment in subsidiary companies.

Article 5: The Company may establish branch offices, factories, and other branches domestically or internationally as needed, in addition to its headquarters located in Taipei City. The establishment, dissolution, or modification of such entities shall be handled in accordance with the resolution of the Board of Directors and after obtaining the approval of the competent authorities.

Article 6: The announcement method of this company shall be handled in accordance with Article 28 of the Company Act.

Chapter II Shares

Article 7: The total capital of the company is set at NTD 300 million, divided into 30 million shares, with a par value of NTD 10 per share. The Board of Directors is authorized to issue shares in multiple tranches as needed. The aforementioned total capital includes a reserve of NTD 100 million, divided into 10 million shares, with a par value of NTD 10 per share, for the purpose of issuing stock certificates for rights offering.

Article 8: The company may transfer repurchased shares to employees at a price lower than the actual repurchase price, or issue employee stock options at a price lower than the closing price on the day of issuance, with the approval of a shareholder meeting attended by more than half of the total issued shares represented by shareholders and with the consent of shareholders representing more than two-thirds of the voting rights present at the meeting.

Article 9: The registered shares issued by our company are exempt from printing stock certificates, but they must be registered with the securities central depository institution. If stock certificates are printed, they will be signed or stamped by the director representing the company and issued after being legally certified. According to Article 267 of the Company Law, employees of our company who subscribe for new shares may not transfer them within two years without the company's consent, otherwise the transfer will be invalid.

Article 10: The handling of shareholder affairs in our company is carried out in accordance with the "Guidelines for the Handling of Shareholder Affairs of Publicly Traded Companies" issued by the competent authority and relevant laws and regulations such as the Company Law.

Chapter III Shareholders' Meeting

Article 11: There are two types of shareholder meetings: regular and special. The regular meeting is held once a year within six months after the end of each fiscal year, convened by the Board of Directors in accordance with the law. The special meeting is called when necessary in accordance with the law. For the convening of shareholder meetings, the notice of a regular meeting should be given to the shareholders at least thirty days prior to the meeting, while the notice of a special meeting should be given to

the shareholders at least fifteen days prior to the meeting.

The company's shareholders' meeting can be held via video conference or other methods announced by the central competent authority.

Article 12: The voting rights of shareholders in our company are handled in accordance with the relevant provisions of the Company Law and the securities regulator.

Article 13: If a shareholder is unable to attend a shareholder meeting due to certain circumstances, he or she may issue a proxy with the authorized scope specified by the company to appoint a representative to attend the meeting on his or her behalf. The method of proxy attendance by shareholders is governed by the "Rules Governing the Use of Proxies to Attend Shareholder Meetings of Publicly Traded Companies" issued by the competent authority, in addition to the provisions of Article 177 of the Company Law.

Article 14: Unless otherwise provided by relevant laws and regulations, the resolution of a shareholder meeting shall be passed with the approval of more than half of the voting rights present in person or by proxy of the total number of issued shares represented at the meeting.

Article 15: The shareholder meeting is convened by the Board of Directors, with the chairman of the board serving as the chairman of the meeting. In the event that the chairman of the board is absent, a director designated by the chairman of the board shall act as a proxy. If no one is designated, a director shall be elected by the board to act as a proxy. If the meeting is convened by someone other than the Board of Directors, the chairman of the meeting shall be appointed by the convener. If there are two or more conveners, they shall jointly elect a chairman of the meeting.

Article 16: The resolutions passed at the shareholder meeting shall be recorded in the minutes, which shall include the date, location, number of shareholders present, number of shares and voting rights represented, the name of the chairman, the resolutions and the methods of adoption. The minutes shall be signed or sealed by the chairman of the meeting and distributed to all shareholders within 20 days after the meeting. The minutes, along with the attendance sign-in sheet and proxy forms, shall be kept by the company. The distribution of the minutes may be made by public notice.

Chapter IV Director, Board of Directors and Managers

Article 17: Understood. According to the "Regulations Governing the Ownership Percentage of Shares Held by Directors and Supervisors of Public Companies" promulgated by the competent authority, the percentage of shares held by each director should be disclosed in the company's annual report. The percentage of shares held by all directors combined should not be less than 1% of the total number of outstanding shares of the company.

Article 18: According to Article 14-4 of the Securities and Exchange Act, this company has established an Audit Committee, which shall be composed of all independent directors. The Audit Committee or its members shall be responsible for performing the duties of a supervisor as provided by the Company Act, the Securities and Exchange Act, and other applicable laws and regulations.

Article 19: The Company has established a Remuneration Committee in accordance with Article 14-6 of the Securities and Exchange Act. The Remuneration Committee shall exercise its powers in accordance with the Regulations Governing the Establishment and Exercise of Powers by Remuneration Committees of Companies Listed on the Stock Exchange or Traded

Over-the-Counter at Securities Firms.

Article 20: The Board of Directors should be composed of two-thirds or more of the directors present, and the majority of the attending directors must agree to elect one person as the chairman and another person as the vice chairman. The chairman represents the company externally and may appoint one director to act on behalf of the chairman and hold office as needed for business purposes.

Article 21: When one-third or more of the directors' seats are vacant or all independent directors are dismissed, the Board of Directors should convene a special shareholders' meeting within 60 days to fill the vacancies. The term of office for the newly elected directors is limited to the remainder of the original term.

Article 22: The Board of Directors is convened by the chairman. The decisions of the Board of Directors, except as otherwise provided by the Company Law, shall require the presence of more than half of the directors, and the approval of the majority of the attending directors. If a director is unable to attend due to reasons, they may issue a proxy specifying the scope of authorization and entrust another director to attend on their behalf. The proxy shall be limited to one person.

Article 23: The convocation of the Board of Directors should specify the reason and notify all directors at least seven days in advance. However, in case of emergency, the board may be convened at any time.

The notice of convocation may be delivered in writing, by fax, or electronically.

Article 24: The powers of the Board of Directors are as follows: :

The formulation of business policies and the supervision of the execution of business plans.
The review of proposed budgets.
The revision of the company's capital.
The review of profit distribution.
The approval of important external contracts.
The proposal of amendments to the company's articles of incorporation.
The approval of the company's organizational regulations and important bylaws.
The approval of the establishment, restructuring, or dissolution of branch offices or factories.
The appointment or dismissal of important personnel of the company.
The convocation of shareholder meetings.
The determination of other important matters.

Article 25: The remuneration of all directors shall be authorized by the Board of Directors. Regardless of the operating profit or loss, the remuneration shall be given according to the usual industry standards. The company may purchase liability insurance for directors within their term of office, for the scope of duties executed by the company.

Article 26: The company may appoint managers, whose appointment, dismissal, and remuneration shall be handled in accordance with Article 29 of the Company Act.

The company may purchase liability insurance for managers within the scope of duties executed by the company. Chapter V Accounting

Chapter V Accounting

Article 27: The company shall prepare the following documents at the end of each fiscal year, and submit them to the regular shareholders' meeting for approval in accordance with the law:

Business Report
Financial Statements
Proposal for distribution of profits or allocation of losses

Article 28: If the Company has profits in a fiscal year (where “profits” refer to profit before tax prior to the deduction of employee compensation and directors’ remuneration), after first setting aside an amount to cover accumulated losses, if there is any remaining balance, 3% to 6% shall be appropriated as employee compensation (of which no less than 20% shall be allocated as compensation for grassroots employees), and not more than 4% shall be appropriated as directors’ remuneration. Such appropriations shall be resolved by the Board of Directors with the attendance of more than two-thirds of the directors and the approval of a majority of the directors present.

The employee compensation and grassroots employee compensation referred to in the preceding paragraph may be distributed in the form of shares or cash, and the recipients may include employees of subordinate companies who meet certain specified conditions.

Article 29: If this company has a profit in each fiscal year, after paying all taxes, making up for accumulated losses, and allocating the statutory reserve and other special reserve as required by law, the remaining profit, along with the undistributed profit from previous years, shall be used to formulate a profit distribution proposal by the Board of Directors. At least 10% of the profit shall be allocated and submitted to the shareholders' meeting for resolution, taking into account the company's long-term development plans and maintaining a sound financial structure.

The company's dividend policy shall be based on the profit situation, and shall balance between cash dividends and stock dividends in an appropriate proportion. If stock dividends are distributed, they shall account for at least 10% of the total dividends for that fiscal year.

Chapter VI Supplementary Provisions

Article 30: If there are any matters not covered in this Articles of Association, they shall be handled in accordance with the provisions of the Company Act and relevant laws and regulations.

Article 31: These Articles of Incorporation were enacted on August 27, 1976. The 1st amendment was made on February 25, 1977. The 2nd amendment was made on July 6, 1977. The 3rd amendment was made on February 2, 1978. The 4th amendment was made on September 3, 1978. The 5th amendment was made on April 16, 1979. The 6th amendment was made on September 24, 1979. The 7th amendment was made on December 28, 1979. The 8th amendment was made on October 16, 1980. The 9th amendment was made on January 12, 1983. The 10th amendment was made on May 31, 1984. The 11th amendment was made on July 7, 1984. The 12th amendment was made on October 1985. The 13th amendment was made on April 5th, 1987. The 14th amendment was made on January 24, 1988. The 15th amendment was made on January 5, 1989. The 16th amendment was made on December 1, 1989. The 17th amendment was made on February 4, 1990. The 18th amendment was made

on September 5,1990. The 19th amendment was made on March 23, 1991. The 20th amendment was made on June 12, 1993. The 21th amendment was made on June 3, 1994. The 22th amendment was made on June 17, 1995. The 23th amendment was made on June 15, 1996. The 24th amendment was made on April 30, 1997. The 25th amendment was made on April 30, 1998. The 26th amendment was made on April 30, 1999. The 27th and The 28th amendment was made on May 19, 2000. The 29th amendment was made on May 18, 2001. The 30th amendment was made on June 28, 2002. The 31th amendment was made on June 25, 2004. The 32th amendment was made on June 10, 2005. The 33th amendment was made on June 14, 2006. The 34th amendment was made on June 13, 2007. The 35th amendment was made on June 13, 2008. The 36th amendment was made on June 19, 2009. The 37th amendment was made on June 18,2010. The 38th amendment was made on June 15, 2011. The 39th amendment was made on June 15, 2012. The 40th amendment was made on June 18, 2014. The 41th amendment was made on May 31, 2016. The 42th amendment was made on May 27, 2020. The 43th amendment was made on May 26, 2023. The 44th amendment was made on May 29, 2024. The 45th amendment was made on June 5, 2025.

Appendix 3

Maywufa Company Limited
Rules for Director Elections

Article 1: To ensure fair, just, and transparent election of directors, this procedure is established in accordance with Article 21 of the "Corporate Governance Best Practice Principles for Listed and OTC Companies."

Article 2: The election of directors in our company shall be conducted in accordance with the provisions of this procedure, except as otherwise provided by laws or the company's articles of incorporation.

Article 3: The selection of directors in this company should take into account the overall composition of the board of directors. The composition of the board of directors should consider diversity, and appropriate diversity policies should be formulated based on its own operations, business type, and development needs. These policies should include but not be limited to the following two aspects:

Basic conditions and values: gender, age, nationality, culture, etc.
Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing, or technology), professional skills, and industry experience, etc.

The members of the board of directors should generally possess the knowledge, skills, and qualities necessary for performing their duties. The overall abilities that they should possess are as follows:

Operational judgment ability.
Accounting and financial analysis ability.
Management ability.
Crisis handling ability.
Industry knowledge.
International market perspective.
Leadership ability.
Decision-making ability.

More than half of the seats on the board of directors should not be held by individuals who have a spouse or a relative within two degrees of kinship.

Article 4: The qualifications and selection of independent directors of this company shall comply with the relevant provisions of the "Regulations Governing the Establishment of Independent Directors for Publicly Issued Companies and Matters to Be Followed" and shall be handled in accordance with Article 24 of the "Corporate Governance Best Practice Principles for Listed and OTC Companies".

Article 5: The election of directors in this company shall follow the procedures of candidate nomination system as prescribed in Article 192-1 of the Company Act. In case of dismissal of directors due to reasons, resulting in the number of directors being less than five, the company shall hold a by-election at the nearest shareholders' meeting. However, if the number of vacancies for directors reaches one-third of the seats stipulated in the articles of association, the company shall hold a special shareholders' meeting to fill the vacancies within 60 days from the occurrence of the fact.

If the number of independent directors is insufficient according to the provisions of Subparagraph 1, Paragraph 2 of Article 14-2 of the Securities and Exchange Act, the company shall make up for the vacancy at the nearest shareholders' meeting. If all independent directors are dismissed, the company shall hold a special shareholders' meeting

within 60 days from the occurrence of the fact to elect new independent directors.

Article 6: The election of the directors of this company adopts the system of cumulative voting by a single ballot, and each share has the same number of voting rights as the number of directors to be elected. Shareholders can concentrate their votes on one candidate or distribute their votes among multiple candidates.

Article 7: The Board of Directors should prepare election ballots equal to the number of directors to be elected and indicate the voting rights on each ballot. The ballots should be distributed to the shareholders attending the shareholders' meeting, and the names of the voters may be recorded on the ballots by filling in their attendance registration number.

Article 8: The number of directors in this company is determined by the company's articles of association, and the election rights of independent directors and non-independent directors are counted separately. The candidate who receives the most votes representing the election rights for each category of director will be elected in order. In case there are two or more candidates with the same number of votes and exceeding the prescribed number of seats, they will be determined by drawing lots. If a candidate is absent, the chairman shall draw lots on their behalf.

Article 9: Before the start of the election, the chairman should designate several shareholders as inspectors and vote counters to perform their duties. The ballot box should be prepared by the board of directors and opened for inspection by the inspectors before the vote.

Article 10: Invalid ballots shall include any of the following circumstances:

Ballots not prepared by the convener.
Blank ballots submitted to the ballot box.
Illegible or altered handwriting.
The name of the candidate written on the ballot does not match the list of nominated directors.
Other words or phrases written on the ballot in addition to the assigned voting rights.
Two or more candidates selected on the same ballot.

Article 11: After the voting is completed, the ballots shall be counted on the spot, and the result of the count shall be announced on the spot by the chairman or a person designated by the chairman, including the list of elected directors and their number of votes.

The ballots for the election shall be sealed and signed by the scrutineers and properly kept for at least one year. However, if shareholders file a lawsuit under Article 189 of the Company Law, they shall be kept until the end of the litigation.

Article 12: This regulation shall take effect after being passed by the shareholders' meeting, and the same shall apply when it is revised.

This regulation was established on April 30, 1999. The 1st amendment was made on June 28, 2002. The 2nd amendment was made on May 31, 2016. The 3rd amendment was made on May 27, 2020. The 4th amendment was made on July 16, 2021

Appendix 4

Maywufa Company Limited Shareholdings of Directors

Directors' Stockholding Status:

April 12, 2026

Job Title	Name	Shares held in share register (shares)	Remark
Chairman	Cheng Yi Investment Company Limited	23,594,819	Representative : Lee Chen-Chia
Vice Chairman	Cheng Yi Investment Company Limited	23,594,819	Representative : Lee Yi-Li
Director	Li Ling Investment Company Limited	14,946,556	Representative : Lee I-Lin
Director	Cheng Yi Investment Company Limited	23,594,819	Representative : Lai Yu-Ju
Director	Hua Wei Ltd.	78,000	Representative : Chen Wen-Hwa
Director	Yi Xin International Company Limited	1,120,000	Representative : Lee Yu-Chia
Director	Li Ling Investment Company Limited	14,946,556	Representative : Lee Bi-Jen
Director	Hua Wei Ltd.	78,000	Representative : Liu Wen-Zheng
Director	Yi Xin International Company Limited	1,120,000	Representative : Yu Chang-Min
Independent Director	Chen Hui-Yiu	0
Independent Director	Ou Shu-Fang	0
Independent Director	Chang Hong-Jen	0
Independent Director	Lin Chi-Feng	0

The minimum number of shares held by all directors and the detailed list of the number of shares held by the shareholder register:

April 12, 2026

Job Title	Number of shares to be held (shares)	Number of shares registered in the register of shareholders (shares)
Director	8,000,000	39,739,375

Remarks:

(1). The paid-in capital of the company is NT $1,329,152,440, divided into 132,915,244 shares.
(2). The company has set up two or more independent directors. According to Article 2 of the "Public Issuance Company Directors, Supervisors' Shareholding Ratio and Inspection Implementation Rules", the shareholding ratio calculated by the minimum shareholding ratio of all directors is reduced to Eighty percent.
(3). Independent directors are not included in the shareholding of director.

AI assistant

Maywufa — AGM Information 2026

51908_rns_2026-05-22_f44c666a-1553-47d5-8a39-13afa92cd159.pdf

美吾華股份有限公司

Handbook for the 2026 Annual Meeting of Shareholders

Table of Contents

II. Meeting Agenda

1. Report Items

2. Acknowledged Matters

4. Other Matters

5. Extemporary Motions

6. Adjournment

Maywufa Company Limited

The 2026 Business Report

II.2025 Results of Business Plan Implementation

III. Budget Execution Status

Maywufa Company Limited

The Comparison Table of Sustainable Development Best Practice Principles

INDEPENDENT AUDITORS' REPORT

Opinion

Basis for Opinion

Key Audit Matters

Other Matters

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Notice to Readers

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

MAYWUFA COMPANY LTD. AND SUBSIDIARIES

INDEPENDENT AUDITORS' REPORT

Opinion

Basis for Opinion

Key Audit Matters

The Validity of Occurrence of Revenue Recognition

Other Matters

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Auditors' Responsibilities for the Audit of the Financial Statements

Notice to Readers

MAYWUFA COMPANY LTD.

MAYWUFA COMPANY LTD.

Maywufa Company Limited

Director and Independent Director Candidates

Chapter II Shares

Chapter III Shareholders' Meeting

Chapter IV Director, Board of Directors and Managers

Chapter V Accounting

Chapter VI Supplementary Provisions

Maywufa Company Limited Shareholdings of Directors

More from Maywufa

Maywufa AGM Information 2026